S'abonner

Contemporary epidemiology of infective endocarditis in patients with congenital heart disease: A UK prospective study - 05/08/19

Doi : 10.1016/j.ahj.2019.05.014 
TJ Cahill, MRCP DPhil a, 1, PD Jewell, BM BCh b, 1, L Denne c, RC Franklin, MBBS MD d, A Frigiola, MD e, E Orchard, MA MRCP a, BD Prendergast, DM FRCP e,
a Oxford Heart Centre, Oxford University Hospitals, Oxford, UK 
b Imperial College Healthcare NHS Trust, London, UK 
c National Institute for Cardiovascular Outcomes Research, Bart's Health NHS Trust, London, UK 
d Department of Paediatric Cardiology, Royal Brompton Hospital, London, UK 
e Department of Cardiology, St Thomas' Hospital, London, UK 

Reprint requests: Professor B.D. Prendergast DM FRCP, Department of Cardiology, St Thomas' Hospital, London, UKDepartment of Cardiology, St Thomas' HospitalLondonUK

Abstract

Objectives

Infective endocarditis is a life-threatening complication of congenital heart disease (CHD), but there are few studies concerning the contemporary risk profile, preceding invasive procedures and outcomes in this patient population. The aim of this study was to investigate the epidemiology of infective endocarditis (IE) in patients with CHD.

Methods

Cases of IE in children and adults with CHD were prospectively recorded as part of the UK National Institute for Cardiovascular Outcomes Research (NICOR) National Congenital Heart Disease Audit. Patients were entered into the database between April 2008 and March 2016.

Results

Eight hundred episodes of IE were recorded in 736 patients with CHD. Sixty-five patients (9%) were infants (aged <1 year), 235 (32%) were children (aged 1–15 years), and 436 (59%) were adults (aged >15 years). The most common diagnoses were Tetralogy of Fallot (n = 150, 22.8%), ventricular septal defect (n = 129, 19.6%) and bicuspid aortic valve (n = 70, 10.7%). Dental procedures preceded 67 of 635 episodes (11%) of IE, and non-dental invasive procedures preceded 177 of 644 episodes (27.4%). The most common causative organisms were streptococci, accounting for 40% of cases. Overall in-hospital mortality was 6.7%. On multivariable analysis, adverse factors associated with in-hospital mortality were staphylococcal infection and presence of an underlying atrioventricular septal defect.

Conclusions

Infective endocarditis in patients with CHD is an ongoing clinical challenge. In contemporary practice in tertiary congenital centers, 1 of 15 patients do not survive to hospital discharge. Streptococci remain the most common causative organism, and antecedent dental or medical procedures were undertaken in a significant minority in the 3 months before diagnosis. The presence of an atrioventricular septal defect or staphylococcal infection is associated with significantly increased risk of early mortality.

Le texte complet de cet article est disponible en PDF.

Abbreviations : AS, AR, ASD, AVSD, PDA, TGA, TOF, VSD, UVH


Plan


 Contributions
Thomas Cahill: conceptualization, data curation, writing—original draft preparation, investigation. Paul Jewell: data curation, investigation, writing—original draft preparation. Lin Denne: data curation. Rodney Franklin: conceptualization, writing—review & editing, methodology. Alessandra Frigiola: data curation, writing—review & editing. Elizabeth Orchard: data curation, writing—review & editing. Bernard Prendergast: conceptualization, methodology, writing—original draft preparation, supervision.


© 2019  Elsevier Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 215

P. 70-77 - septembre 2019 Retour au numéro
Article précédent Article précédent
  • The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: A pilot randomized placebo controlled trial of colchicine following acute myocardial infarction
  • Thomas Hennessy, Linda Soh, Mitchell Bowman, Rahul Kurup, Carl Schultz, Sanjay Patel, Graham S. Hillis
| Article suivant Article suivant
  • Long-term follow-up and safety assessment of angiogenic gene therapy trial VIF-CAD: Transcatheter intramyocardial administration of a bicistronic plasmid expressing VEGF-A165/bFGF cDNA for the treatment of refractory coronary artery disease
  • Krzysztof Kuku?a, Arkadiusz Urbanowicz, Mariusz K?opotowski, Maciej D?browski, Jerzy Pr?gowski, Jacek K?dziela, Zbigniew Chmielak, Adam Witkowski, Witold Ru?y??o

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.